Skip to main content
. 2017 Aug 7;8(47):82897–82909. doi: 10.18632/oncotarget.19970

Figure 6. Crenolanib reduces the mutant-KIT population in ex vivo mastocytosis and acute leukemia viability assays.

Figure 6

SM: Cells were stained for CD25 to characterize the mast cell cohort and reduction of the viable cells was assessed flow cytometrically 48 hours after treatment with crenolanib in dose dilution series (A-C). An exemplary representative assay is provided. A box whisker plot, including comparative analysis of crenolanib (Cb, nM) and dasatinib (Dasa, nM), is provided (D) for all patients. CBF AML: Reduction of the viable CD45-low cell cohort exposed to crenolanib for 48 hours was determined flow cytometrically in a native sample of a patient diagnosed with KIT D816V positive core binding factor leukemia (E, F). Box whisker plots are provided (G-1, KIT wildtype and G-2, KIT D816V) for all tested patients. (H) Comparative analysis using dasatinib is provided for the patient shown in 6E/F. LL lower left quadrant, LR lower right quadrant, UR upper right quadrant.